Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLD-MI
NCT04420624Phase 3Terminated
- Sponsor
- CHU Montpellier
- Start
- Dec 2020
- Primary completion
- May 2022
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised trial of colchicine in myocardial infarction (MI) (2 arms), sponsored by CHU Montpellier. Primary endpoint: Percentage of myocardial denervation at 6 months. Started Dec 2020; status: terminated.
02
Drugs
colchicine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT04420624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04420624.